

# Global Blood Cancer Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G91967CAA92EN.html>

Date: May 2026

Pages: 105

Price: US\$ 3,480.00 (Single User License)

ID: G91967CAA92EN

## Abstracts

According to our (Global Info Research) latest study, the global Blood Cancer Drugs market size was valued at US\$ 76765 million in 2025 and is forecast to a readjusted size of US\$ 141168 million by 2032 with a CAGR of 9.0% during review period.

Blood cancer drugs are a class of medications used for the prevention, control, or treatment of malignant diseases of the hematologic system, including leukemia, lymphoma, multiple myeloma, and other related blood cancers. These drugs include chemotherapeutic agents, targeted therapies, immunomodulators, and cell-based immunotherapies, working through mechanisms such as inhibition of cancer cell proliferation, induction of apoptosis, or activation of the immune system. The development and application of blood cancer drugs emphasize precision and individualized therapy, leveraging molecular targets and biomarkers to tailor treatment plans to specific patient populations. Advances in molecular biology, immunology, and genomics continue to expand treatment strategies, improving therapeutic outcomes while reducing adverse effects, and providing patients with more effective and sustainable management of blood cancers.

The incidence of blood cancers is steadily increasing, driven by aging populations and environmental factors, providing a growing market demand. The widespread adoption of precision medicine and individualized therapy has made targeted drugs, immunotherapies, and cell-based treatments preferred clinical options. Advancements in novel molecular targeted therapies and immunomodulators offer additional treatment approaches. Support from global healthcare systems for high-value innovative drugs, coupled with expanding insurance coverage, enhances patient access and market potential. Meanwhile, advanced diagnostic technologies enable early detection and disease subtyping, further increasing drug utilization and market size. Blood cancer

drug development is costly, time-consuming, and carries high failure risks, creating significant entry barriers. Some novel therapies are constrained by complex manufacturing processes and stringent quality control, leading to production and supply chain risks. High drug costs and healthcare reimbursement policies may limit market access and profitability. Clinical application requires skilled physicians and optimized treatment plans, increasing education and promotion costs. Additionally, drug resistance and potential side effects during therapy can affect long-term market performance. Clinical demand is trending toward precision, personalization, and combination therapies. Patients and physicians increasingly value efficacy, safety, and quality of life, driving demand for low-toxicity drugs and combination regimens. Expansion of primary care and specialty centers broadens the application settings, requiring more convenient preparation and administration. As individualized treatment strategies become more widespread, gene profiling and molecular target-guided therapy are emerging as market trends, promoting diversity and differentiation in blood cancer drug offerings. Upstream materials for blood cancer drugs mainly include active pharmaceutical ingredients, chemical synthesis precursors, biological cell lines, and delivery or sustained-release materials. The active ingredients directly determine efficacy and therapeutic options, while the purity and controllability of chemical and biological materials are critical for product safety and consistency. Complex manufacturing processes and strict quality control standards pose supply chain stability challenges. With advances in biopharmaceutical and synthetic technologies, localization of key raw materials is accelerating, though stringent requirements for batch consistency and process optimization remain.

This report is a detailed and comprehensive analysis for global Blood Cancer Drugs market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

### **Key Features:**

Global Blood Cancer Drugs market size and forecasts, in consumption value (\$ Million), 2021-2032

Global Blood Cancer Drugs market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global Blood Cancer Drugs market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global Blood Cancer Drugs market shares of main players, in revenue (\$ Million), 2021-2026

### **The Primary Objectives in This Report Are:**

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Blood Cancer Drugs

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Blood Cancer Drugs market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Bristol-Myers Squibb, Johnson & Johnson, AbbVie, Novartis, Roche, Amgen, Takeda, Pfizer, AstraZeneca, Gilead Sciences, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

### Market segmentation

Blood Cancer Drugs market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

### Market segment by Type

Targeted Therapy

Chemotherapy

Immunotherapy

Other

#### Market segment by Route of Administration

Oral

Injection

Others

#### Market segment by Sales Channel

Hospital

Clinic

Other

#### Market segment by Application

Leukemia

lymphoma

Multiple Myeloma

#### Market segment by players, this report covers

Bristol-Myers Squibb

Johnson & Johnson

AbbVie

Novartis

Roche

Amgen

Takeda

Pfizer

AstraZeneca

Gilead Sciences

Sanofi

Incyte Corporation

BeiGene

Astellas Pharma

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

**The content of the study subjects, includes a total of 13 chapters:**

Chapter 1, to describe Blood Cancer Drugs product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Blood Cancer Drugs, with revenue, gross margin, and global market share of Blood Cancer Drugs from 2021 to 2026.

Chapter 3, the Blood Cancer Drugs competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and Blood Cancer Drugs market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Blood Cancer Drugs.

Chapter 13, to describe Blood Cancer Drugs research findings and conclusion.

## Contents

### 1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of Blood Cancer Drugs by Type

1.3.1 Overview: Global Blood Cancer Drugs Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global Blood Cancer Drugs Consumption Value Market Share by Type in 2025

1.3.3 Targeted Therapy

1.3.4 Chemotherapy

1.3.5 Immunotherapy

1.3.6 Other

1.4 Classification of Blood Cancer Drugs by Route of Administration

1.4.1 Overview: Global Blood Cancer Drugs Market Size by Route of Administration: 2021 Versus 2025 Versus 2032

1.4.2 Global Blood Cancer Drugs Consumption Value Market Share by Route of Administration in 2025

1.4.3 Oral

1.4.4 Injection

1.4.5 Others

1.5 Classification of Blood Cancer Drugs by Sales Channel

1.5.1 Overview: Global Blood Cancer Drugs Market Size by Sales Channel: 2021 Versus 2025 Versus 2032

1.5.2 Global Blood Cancer Drugs Consumption Value Market Share by Sales Channel in 2025

1.5.3 Hospital

1.5.4 Clinic

1.5.5 Other

1.6 Global Blood Cancer Drugs Market by Application

1.6.1 Overview: Global Blood Cancer Drugs Market Size by Application: 2021 Versus 2025 Versus 2032

1.6.2 Leukemia

1.6.3 lymphoma

1.6.4 Multiple Myeloma

1.7 Global Blood Cancer Drugs Market Size & Forecast

1.8 Global Blood Cancer Drugs Market Size and Forecast by Region

1.8.1 Global Blood Cancer Drugs Market Size by Region: 2021 VS 2025 VS 2032

- 1.8.2 Global Blood Cancer Drugs Market Size by Region, (2021-2032)
- 1.8.3 North America Blood Cancer Drugs Market Size and Prospect (2021-2032)
- 1.8.4 Europe Blood Cancer Drugs Market Size and Prospect (2021-2032)
- 1.8.5 Asia-Pacific Blood Cancer Drugs Market Size and Prospect (2021-2032)
- 1.8.6 South America Blood Cancer Drugs Market Size and Prospect (2021-2032)
- 1.8.7 Middle East & Africa Blood Cancer Drugs Market Size and Prospect (2021-2032)

## **2 COMPANY PROFILES**

### 2.1 Bristol-Myers Squibb

- 2.1.1 Bristol-Myers Squibb Details
- 2.1.2 Bristol-Myers Squibb Major Business
- 2.1.3 Bristol-Myers Squibb Blood Cancer Drugs Product and Solutions
- 2.1.4 Bristol-Myers Squibb Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Bristol-Myers Squibb Recent Developments and Future Plans

### 2.2 Johnson & Johnson

- 2.2.1 Johnson & Johnson Details
- 2.2.2 Johnson & Johnson Major Business
- 2.2.3 Johnson & Johnson Blood Cancer Drugs Product and Solutions
- 2.2.4 Johnson & Johnson Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Johnson & Johnson Recent Developments and Future Plans

### 2.3 AbbVie

- 2.3.1 AbbVie Details
- 2.3.2 AbbVie Major Business
- 2.3.3 AbbVie Blood Cancer Drugs Product and Solutions
- 2.3.4 AbbVie Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 AbbVie Recent Developments and Future Plans

### 2.4 Novartis

- 2.4.1 Novartis Details
- 2.4.2 Novartis Major Business
- 2.4.3 Novartis Blood Cancer Drugs Product and Solutions
- 2.4.4 Novartis Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 Novartis Recent Developments and Future Plans

### 2.5 Roche

- 2.5.1 Roche Details

- 2.5.2 Roche Major Business
- 2.5.3 Roche Blood Cancer Drugs Product and Solutions
- 2.5.4 Roche Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Roche Recent Developments and Future Plans
- 2.6 Amgen
  - 2.6.1 Amgen Details
  - 2.6.2 Amgen Major Business
  - 2.6.3 Amgen Blood Cancer Drugs Product and Solutions
  - 2.6.4 Amgen Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.6.5 Amgen Recent Developments and Future Plans
- 2.7 Takeda
  - 2.7.1 Takeda Details
  - 2.7.2 Takeda Major Business
  - 2.7.3 Takeda Blood Cancer Drugs Product and Solutions
  - 2.7.4 Takeda Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.7.5 Takeda Recent Developments and Future Plans
- 2.8 Pfizer
  - 2.8.1 Pfizer Details
  - 2.8.2 Pfizer Major Business
  - 2.8.3 Pfizer Blood Cancer Drugs Product and Solutions
  - 2.8.4 Pfizer Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.8.5 Pfizer Recent Developments and Future Plans
- 2.9 AstraZeneca
  - 2.9.1 AstraZeneca Details
  - 2.9.2 AstraZeneca Major Business
  - 2.9.3 AstraZeneca Blood Cancer Drugs Product and Solutions
  - 2.9.4 AstraZeneca Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.9.5 AstraZeneca Recent Developments and Future Plans
- 2.10 Gilead Sciences
  - 2.10.1 Gilead Sciences Details
  - 2.10.2 Gilead Sciences Major Business
  - 2.10.3 Gilead Sciences Blood Cancer Drugs Product and Solutions
  - 2.10.4 Gilead Sciences Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)

- 2.10.5 Gilead Sciences Recent Developments and Future Plans
- 2.11 Sanofi
  - 2.11.1 Sanofi Details
  - 2.11.2 Sanofi Major Business
  - 2.11.3 Sanofi Blood Cancer Drugs Product and Solutions
  - 2.11.4 Sanofi Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.11.5 Sanofi Recent Developments and Future Plans
- 2.12 Incyte Corporation
  - 2.12.1 Incyte Corporation Details
  - 2.12.2 Incyte Corporation Major Business
  - 2.12.3 Incyte Corporation Blood Cancer Drugs Product and Solutions
  - 2.12.4 Incyte Corporation Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.12.5 Incyte Corporation Recent Developments and Future Plans
- 2.13 BeiGene
  - 2.13.1 BeiGene Details
  - 2.13.2 BeiGene Major Business
  - 2.13.3 BeiGene Blood Cancer Drugs Product and Solutions
  - 2.13.4 BeiGene Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.13.5 BeiGene Recent Developments and Future Plans
- 2.14 Astellas Pharma
  - 2.14.1 Astellas Pharma Details
  - 2.14.2 Astellas Pharma Major Business
  - 2.14.3 Astellas Pharma Blood Cancer Drugs Product and Solutions
  - 2.14.4 Astellas Pharma Blood Cancer Drugs Revenue, Gross Margin and Market Share (2021-2026)
  - 2.14.5 Astellas Pharma Recent Developments and Future Plans

### **3 MARKET COMPETITION, BY PLAYERS**

- 3.1 Global Blood Cancer Drugs Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
  - 3.2.1 Market Share of Blood Cancer Drugs by Company Revenue
  - 3.2.2 Top 3 Blood Cancer Drugs Players Market Share in 2025
  - 3.2.3 Top 6 Blood Cancer Drugs Players Market Share in 2025
- 3.3 Blood Cancer Drugs Market: Overall Company Footprint Analysis
  - 3.3.1 Blood Cancer Drugs Market: Region Footprint

- 3.3.2 Blood Cancer Drugs Market: Company Product Type Footprint
- 3.3.3 Blood Cancer Drugs Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

## **4 MARKET SIZE SEGMENT BY TYPE**

- 4.1 Global Blood Cancer Drugs Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global Blood Cancer Drugs Market Forecast by Type (2027-2032)

## **5 MARKET SIZE SEGMENT BY APPLICATION**

- 5.1 Global Blood Cancer Drugs Consumption Value Market Share by Application (2021-2026)
- 5.2 Global Blood Cancer Drugs Market Forecast by Application (2027-2032)

## **6 NORTH AMERICA**

- 6.1 North America Blood Cancer Drugs Consumption Value by Type (2021-2032)
- 6.2 North America Blood Cancer Drugs Market Size by Application (2021-2032)
- 6.3 North America Blood Cancer Drugs Market Size by Country
  - 6.3.1 North America Blood Cancer Drugs Consumption Value by Country (2021-2032)
  - 6.3.2 United States Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 6.3.3 Canada Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 6.3.4 Mexico Blood Cancer Drugs Market Size and Forecast (2021-2032)

## **7 EUROPE**

- 7.1 Europe Blood Cancer Drugs Consumption Value by Type (2021-2032)
- 7.2 Europe Blood Cancer Drugs Consumption Value by Application (2021-2032)
- 7.3 Europe Blood Cancer Drugs Market Size by Country
  - 7.3.1 Europe Blood Cancer Drugs Consumption Value by Country (2021-2032)
  - 7.3.2 Germany Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 7.3.3 France Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 7.3.4 United Kingdom Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 7.3.5 Russia Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 7.3.6 Italy Blood Cancer Drugs Market Size and Forecast (2021-2032)

## **8 ASIA-PACIFIC**

- 8.1 Asia-Pacific Blood Cancer Drugs Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific Blood Cancer Drugs Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific Blood Cancer Drugs Market Size by Region
  - 8.3.1 Asia-Pacific Blood Cancer Drugs Consumption Value by Region (2021-2032)
  - 8.3.2 China Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 8.3.3 Japan Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 8.3.4 South Korea Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 8.3.5 India Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 8.3.6 Southeast Asia Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 8.3.7 Australia Blood Cancer Drugs Market Size and Forecast (2021-2032)

## **9 SOUTH AMERICA**

- 9.1 South America Blood Cancer Drugs Consumption Value by Type (2021-2032)
- 9.2 South America Blood Cancer Drugs Consumption Value by Application (2021-2032)
- 9.3 South America Blood Cancer Drugs Market Size by Country
  - 9.3.1 South America Blood Cancer Drugs Consumption Value by Country (2021-2032)
  - 9.3.2 Brazil Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 9.3.3 Argentina Blood Cancer Drugs Market Size and Forecast (2021-2032)

## **10 MIDDLE EAST & AFRICA**

- 10.1 Middle East & Africa Blood Cancer Drugs Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa Blood Cancer Drugs Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa Blood Cancer Drugs Market Size by Country
  - 10.3.1 Middle East & Africa Blood Cancer Drugs Consumption Value by Country (2021-2032)
  - 10.3.2 Turkey Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 10.3.3 Saudi Arabia Blood Cancer Drugs Market Size and Forecast (2021-2032)
  - 10.3.4 UAE Blood Cancer Drugs Market Size and Forecast (2021-2032)

## **11 MARKET DYNAMICS**

- 11.1 Blood Cancer Drugs Market Drivers
- 11.2 Blood Cancer Drugs Market Restraints

11.3 Blood Cancer Drugs Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

## **12 INDUSTRY CHAIN ANALYSIS**

12.1 Blood Cancer Drugs Industry Chain

12.2 Blood Cancer Drugs Upstream Analysis

12.3 Blood Cancer Drugs Midstream Analysis

12.4 Blood Cancer Drugs Downstream Analysis

## **13 RESEARCH FINDINGS AND CONCLUSION**

## **14 APPENDIX**

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

## List Of Tables

### LIST OF TABLES

Table 1. Global Blood Cancer Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global Blood Cancer Drugs Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032

Table 3. Global Blood Cancer Drugs Consumption Value by Sales Channel, (USD Million), 2021 & 2025 & 2032

Table 4. Global Blood Cancer Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 5. Global Blood Cancer Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 6. Global Blood Cancer Drugs Consumption Value by Region (2027-2032) & (USD Million)

Table 7. Bristol-Myers Squibb Company Information, Head Office, and Major Competitors

Table 8. Bristol-Myers Squibb Major Business

Table 9. Bristol-Myers Squibb Blood Cancer Drugs Product and Solutions

Table 10. Bristol-Myers Squibb Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 11. Bristol-Myers Squibb Recent Developments and Future Plans

Table 12. Johnson & Johnson Company Information, Head Office, and Major Competitors

Table 13. Johnson & Johnson Major Business

Table 14. Johnson & Johnson Blood Cancer Drugs Product and Solutions

Table 15. Johnson & Johnson Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 16. Johnson & Johnson Recent Developments and Future Plans

Table 17. AbbVie Company Information, Head Office, and Major Competitors

Table 18. AbbVie Major Business

Table 19. AbbVie Blood Cancer Drugs Product and Solutions

Table 20. AbbVie Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 21. Novartis Company Information, Head Office, and Major Competitors

Table 22. Novartis Major Business

Table 23. Novartis Blood Cancer Drugs Product and Solutions

Table 24. Novartis Blood Cancer Drugs Revenue (USD Million), Gross Margin and

## Market Share (2021-2026)

Table 25. Novartis Recent Developments and Future Plans

Table 26. Roche Company Information, Head Office, and Major Competitors

Table 27. Roche Major Business

Table 28. Roche Blood Cancer Drugs Product and Solutions

Table 29. Roche Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 30. Roche Recent Developments and Future Plans

Table 31. Amgen Company Information, Head Office, and Major Competitors

Table 32. Amgen Major Business

Table 33. Amgen Blood Cancer Drugs Product and Solutions

Table 34. Amgen Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 35. Amgen Recent Developments and Future Plans

Table 36. Takeda Company Information, Head Office, and Major Competitors

Table 37. Takeda Major Business

Table 38. Takeda Blood Cancer Drugs Product and Solutions

Table 39. Takeda Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 40. Takeda Recent Developments and Future Plans

Table 41. Pfizer Company Information, Head Office, and Major Competitors

Table 42. Pfizer Major Business

Table 43. Pfizer Blood Cancer Drugs Product and Solutions

Table 44. Pfizer Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 45. Pfizer Recent Developments and Future Plans

Table 46. AstraZeneca Company Information, Head Office, and Major Competitors

Table 47. AstraZeneca Major Business

Table 48. AstraZeneca Blood Cancer Drugs Product and Solutions

Table 49. AstraZeneca Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 50. AstraZeneca Recent Developments and Future Plans

Table 51. Gilead Sciences Company Information, Head Office, and Major Competitors

Table 52. Gilead Sciences Major Business

Table 53. Gilead Sciences Blood Cancer Drugs Product and Solutions

Table 54. Gilead Sciences Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 55. Gilead Sciences Recent Developments and Future Plans

Table 56. Sanofi Company Information, Head Office, and Major Competitors

- Table 57. Sanofi Major Business
- Table 58. Sanofi Blood Cancer Drugs Product and Solutions
- Table 59. Sanofi Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 60. Sanofi Recent Developments and Future Plans
- Table 61. Incyte Corporation Company Information, Head Office, and Major Competitors
- Table 62. Incyte Corporation Major Business
- Table 63. Incyte Corporation Blood Cancer Drugs Product and Solutions
- Table 64. Incyte Corporation Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 65. Incyte Corporation Recent Developments and Future Plans
- Table 66. BeiGene Company Information, Head Office, and Major Competitors
- Table 67. BeiGene Major Business
- Table 68. BeiGene Blood Cancer Drugs Product and Solutions
- Table 69. BeiGene Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 70. BeiGene Recent Developments and Future Plans
- Table 71. Astellas Pharma Company Information, Head Office, and Major Competitors
- Table 72. Astellas Pharma Major Business
- Table 73. Astellas Pharma Blood Cancer Drugs Product and Solutions
- Table 74. Astellas Pharma Blood Cancer Drugs Revenue (USD Million), Gross Margin and Market Share (2021-2026)
- Table 75. Astellas Pharma Recent Developments and Future Plans
- Table 76. Global Blood Cancer Drugs Revenue (USD Million) by Players (2021-2026)
- Table 77. Global Blood Cancer Drugs Revenue Share by Players (2021-2026)
- Table 78. Breakdown of Blood Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3)
- Table 79. Market Position of Players in Blood Cancer Drugs, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025
- Table 80. Head Office of Key Blood Cancer Drugs Players
- Table 81. Blood Cancer Drugs Market: Company Product Type Footprint
- Table 82. Blood Cancer Drugs Market: Company Product Application Footprint
- Table 83. Blood Cancer Drugs New Market Entrants and Barriers to Market Entry
- Table 84. Blood Cancer Drugs Mergers, Acquisition, Agreements, and Collaborations
- Table 85. Global Blood Cancer Drugs Consumption Value (USD Million) by Type (2021-2026)
- Table 86. Global Blood Cancer Drugs Consumption Value Share by Type (2021-2026)
- Table 87. Global Blood Cancer Drugs Consumption Value Forecast by Type (2027-2032)

Table 88. Global Blood Cancer Drugs Consumption Value by Application (2021-2026)

Table 89. Global Blood Cancer Drugs Consumption Value Forecast by Application (2027-2032)

Table 90. North America Blood Cancer Drugs Consumption Value by Type (2021-2026) & (USD Million)

Table 91. North America Blood Cancer Drugs Consumption Value by Type (2027-2032) & (USD Million)

Table 92. North America Blood Cancer Drugs Consumption Value by Application (2021-2026) & (USD Million)

Table 93. North America Blood Cancer Drugs Consumption Value by Application (2027-2032) & (USD Million)

Table 94. North America Blood Cancer Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 95. North America Blood Cancer Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 96. Europe Blood Cancer Drugs Consumption Value by Type (2021-2026) & (USD Million)

Table 97. Europe Blood Cancer Drugs Consumption Value by Type (2027-2032) & (USD Million)

Table 98. Europe Blood Cancer Drugs Consumption Value by Application (2021-2026) & (USD Million)

Table 99. Europe Blood Cancer Drugs Consumption Value by Application (2027-2032) & (USD Million)

Table 100. Europe Blood Cancer Drugs Consumption Value by Country (2021-2026) & (USD Million)

Table 101. Europe Blood Cancer Drugs Consumption Value by Country (2027-2032) & (USD Million)

Table 102. Asia-Pacific Blood Cancer Drugs Consumption Value by Type (2021-2026) & (USD Million)

Table 103. Asia-Pacific Blood Cancer Drugs Consumption Value by Type (2027-2032) & (USD Million)

Table 104. Asia-Pacific Blood Cancer Drugs Consumption Value by Application (2021-2026) & (USD Million)

Table 105. Asia-Pacific Blood Cancer Drugs Consumption Value by Application (2027-2032) & (USD Million)

Table 106. Asia-Pacific Blood Cancer Drugs Consumption Value by Region (2021-2026) & (USD Million)

Table 107. Asia-Pacific Blood Cancer Drugs Consumption Value by Region (2027-2032) & (USD Million)

- Table 108. South America Blood Cancer Drugs Consumption Value by Type (2021-2026) & (USD Million)
- Table 109. South America Blood Cancer Drugs Consumption Value by Type (2027-2032) & (USD Million)
- Table 110. South America Blood Cancer Drugs Consumption Value by Application (2021-2026) & (USD Million)
- Table 111. South America Blood Cancer Drugs Consumption Value by Application (2027-2032) & (USD Million)
- Table 112. South America Blood Cancer Drugs Consumption Value by Country (2021-2026) & (USD Million)
- Table 113. South America Blood Cancer Drugs Consumption Value by Country (2027-2032) & (USD Million)
- Table 114. Middle East & Africa Blood Cancer Drugs Consumption Value by Type (2021-2026) & (USD Million)
- Table 115. Middle East & Africa Blood Cancer Drugs Consumption Value by Type (2027-2032) & (USD Million)
- Table 116. Middle East & Africa Blood Cancer Drugs Consumption Value by Application (2021-2026) & (USD Million)
- Table 117. Middle East & Africa Blood Cancer Drugs Consumption Value by Application (2027-2032) & (USD Million)
- Table 118. Middle East & Africa Blood Cancer Drugs Consumption Value by Country (2021-2026) & (USD Million)
- Table 119. Middle East & Africa Blood Cancer Drugs Consumption Value by Country (2027-2032) & (USD Million)
- Table 120. Global Key Players of Blood Cancer Drugs Upstream (Raw Materials)
- Table 121. Global Blood Cancer Drugs Typical Customers

## List Of Figures

### LIST OF FIGURES

Figure 1. Blood Cancer Drugs Picture

Figure 2. Global Blood Cancer Drugs Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Figure 3. Global Blood Cancer Drugs Consumption Value Market Share by Type in 2025

Figure 4. Targeted Therapy

Figure 5. Chemotherapy

Figure 6. Immunotherapy

Figure 7. Other

Figure 8. Global Blood Cancer Drugs Consumption Value by Route of Administration, (USD Million), 2021 & 2025 & 2032

Figure 9. Global Blood Cancer Drugs Consumption Value Market Share by Route of Administration in 2025

Figure 10. Oral

Figure 11. Injection

Figure 12. Others

Figure 13. Global Blood Cancer Drugs Consumption Value by Sales Channel, (USD Million), 2021 & 2025 & 2032

Figure 14. Global Blood Cancer Drugs Consumption Value Market Share by Sales Channel in 2025

Figure 15. Hospital

Figure 16. Clinic

Figure 17. Other

Figure 18. Global Blood Cancer Drugs Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 19. Blood Cancer Drugs Consumption Value Market Share by Application in 2025

Figure 20. Leukemia Picture

Figure 21. lymphoma Picture

Figure 22. Multiple Myeloma Picture

Figure 23. Global Blood Cancer Drugs Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 24. Global Blood Cancer Drugs Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 25. Global Market Blood Cancer Drugs Consumption Value (USD Million)

Comparison by Region (2021 VS 2025 VS 2032)

Figure 26. Global Blood Cancer Drugs Consumption Value Market Share by Region (2021-2032)

Figure 27. Global Blood Cancer Drugs Consumption Value Market Share by Region in 2025

Figure 28. North America Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 29. Europe Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 30. Asia-Pacific Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 31. South America Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 32. Middle East & Africa Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 33. Company Three Recent Developments and Future Plans

Figure 34. Global Blood Cancer Drugs Revenue Share by Players in 2025

Figure 35. Blood Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 36. Market Share of Blood Cancer Drugs by Player Revenue in 2025

Figure 37. Top 3 Blood Cancer Drugs Players Market Share in 2025

Figure 38. Top 6 Blood Cancer Drugs Players Market Share in 2025

Figure 39. Global Blood Cancer Drugs Consumption Value Share by Type (2021-2026)

Figure 40. Global Blood Cancer Drugs Market Share Forecast by Type (2027-2032)

Figure 41. Global Blood Cancer Drugs Consumption Value Share by Application (2021-2026)

Figure 42. Global Blood Cancer Drugs Market Share Forecast by Application (2027-2032)

Figure 43. North America Blood Cancer Drugs Consumption Value Market Share by Type (2021-2032)

Figure 44. North America Blood Cancer Drugs Consumption Value Market Share by Application (2021-2032)

Figure 45. North America Blood Cancer Drugs Consumption Value Market Share by Country (2021-2032)

Figure 46. United States Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 47. Canada Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 48. Mexico Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Million)

Figure 49. Europe Blood Cancer Drugs Consumption Value Market Share by Type (2021-2032)

Figure 50. Europe Blood Cancer Drugs Consumption Value Market Share by Application (2021-2032)

Figure 51. Europe Blood Cancer Drugs Consumption Value Market Share by Country (2021-2032)

Figure 52. Germany Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 53. France Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 54. United Kingdom Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 55. Russia Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 56. Italy Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 57. Asia-Pacific Blood Cancer Drugs Consumption Value Market Share by Type (2021-2032)

Figure 58. Asia-Pacific Blood Cancer Drugs Consumption Value Market Share by Application (2021-2032)

Figure 59. Asia-Pacific Blood Cancer Drugs Consumption Value Market Share by Region (2021-2032)

Figure 60. China Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 61. Japan Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 62. South Korea Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 63. India Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 64. Southeast Asia Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 65. Australia Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 66. South America Blood Cancer Drugs Consumption Value Market Share by Type (2021-2032)

Figure 67. South America Blood Cancer Drugs Consumption Value Market Share by Application (2021-2032)

Figure 68. South America Blood Cancer Drugs Consumption Value Market Share by Country (2021-2032)

Figure 69. Brazil Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

Figure 70. Argentina Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)

- Figure 71. Middle East & Africa Blood Cancer Drugs Consumption Value Market Share by Type (2021-2032)
- Figure 72. Middle East & Africa Blood Cancer Drugs Consumption Value Market Share by Application (2021-2032)
- Figure 73. Middle East & Africa Blood Cancer Drugs Consumption Value Market Share by Country (2021-2032)
- Figure 74. Turkey Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 75. Saudi Arabia Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 76. UAE Blood Cancer Drugs Consumption Value (2021-2032) & (USD Million)
- Figure 77. Blood Cancer Drugs Market Drivers
- Figure 78. Blood Cancer Drugs Market Restraints
- Figure 79. Blood Cancer Drugs Market Trends
- Figure 80. Porters Five Forces Analysis
- Figure 81. Blood Cancer Drugs Industrial Chain
- Figure 82. Methodology
- Figure 83. Research Process and Data Source

## I would like to order

Product name: Global Blood Cancer Drugs Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G91967CAA92EN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G91967CAA92EN.html>